Omeros Corporation (OMER): Price and Financial Metrics
OMER Price/Volume Stats
| Current price | $2.55 | 52-week high | $7.80 |
| Prev. close | $2.54 | 52-week low | $0.92 |
| Day low | $2.28 | Volume | 913,500 |
| Day high | $2.62 | Avg. volume | 716,072 |
| 50-day MA | $1.87 | Dividend yield | N/A |
| 200-day MA | $4.04 | Market Cap | 160.31M |
OMER Stock Price Chart Interactive Chart >
Omeros Corporation (OMER) Company Bio
Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded in 1994 and is based in Seattle, Washington.
Latest OMER News From Around the Web
Below are the latest news stories about OMEROS CORP that investors may wish to consider to help them evaluate OMER as an investment opportunity.
Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call TranscriptOmeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. After the company’s remarks, we will conduct a question-and-answer session. And please be advised that this call is being recorded at the […] |
Q3 2023 Omeros Corp Earnings CallQ3 2023 Omeros Corp Earnings Call |
Omeros Corporation Reports Third Quarter 2023 Financial ResultsSEATTLE, November 09, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2023, which in |
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023SEATTLE, November 06, 2023--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. |
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathySEATTLE, November 03, 2023--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had "high-risk" TA-TMA. Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was authored by an external group of investigators |
OMER Price Returns
| 1-mo | 87.50% |
| 3-mo | -24.89% |
| 6-mo | -66.00% |
| 1-year | 25.00% |
| 3-year | -81.90% |
| 5-year | -81.81% |
| YTD | 12.83% |
| 2022 | -64.85% |
| 2021 | -54.99% |
| 2020 | 1.38% |
| 2019 | 26.48% |
| 2018 | -42.67% |
Continue Researching OMER
Want to see what other sources are saying about Omeros Corp's financials and stock price? Try the links below:Omeros Corp (OMER) Stock Price | Nasdaq
Omeros Corp (OMER) Stock Quote, History and News - Yahoo Finance
Omeros Corp (OMER) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...